学術雑誌
学会発表
    （最終更新日：2025-08-20 16:11:58）
  ミゾグチ　シンスケ   MIZOGUCHI Shinsuke
  溝口　晋輔
   所属   その他 その他  泌尿器科
   職種   臨床修練生
■ 学術雑誌
1. 原著　 Effect of age on treatment outcomes of first-line immune checkpoint inhibitor combination therapy for previously untreated advanced renal cell carcinoma. 2025/08
2. その他　 Impact of cytoreductive nephrectomy on immune checkpoint inhibitor therapy: Treatment outcomes of immune inhibitors combination therapies for metastatic renal cell carcinoma with primary kidney tumors. 2025/05 Link
3. 原著　 Comparative analysis of outcomes for patients with advanced renal cell carcinoma: Immuno-oncology era versus tyrosine kinase inhibitor era in the IMDC favorable-risk group. 2025/04
4. 原著　 Changes in outcome of patients with advanced non‑clear cell renal cell carcinoma from the tyrosine kinase inhibitor era
to the immuno‑oncology era. 2024/11
5. 原著　 Robot-assisted partial nephrectomy for multiple allograft renal cell carcinomas: A case report. 2024/11
全件表示(13件)
■ 学会発表
1. 網羅的遺伝子発現解析および腫瘍浸潤免疫細胞プロファイリングによる非淡明細胞型腎細胞がんに対する免疫チェックポイント阻害薬治療効果に与える影響の解明 （口頭，一般） 2025/07/05
2. Impact of cytoreductive nephrectomy on immunecheckpoint inhibitor therapy: Treatment outcomes of immune inhibitors combination therapies formetastatic renal cell carcinoma with primary kidneytumors. （ポスター掲示，一般） 2025/04/28
3. Prognostic impact of polypharmacy in immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma. （口頭，一般） 2025/04/18
4. Safety and efficacy of enfortumab vedotin for metastatic urothelial carcinoma in over 80 years old patients: Multi-center retrospective study in Japan. （口頭，一般） 2025/04/18
5. Outcome comparison between nivolumab plus ipilimumab and lenvatinib plus pembrolizumab or nivolumab plus cabozantinib for advanced renal cell carcinoma. （口頭，一般） 2025/04/17
全件表示(32件)